Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
Launched by WONKWANG UNIVERSITY HOSPITAL · Apr 29, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a specific issue that can happen when a medication called sugammadex is used to reverse muscle relaxation during surgery. Specifically, the study wants to understand how often and how severely patients might experience mouth clenching, known as masseter muscle spasm, after receiving sugammadex. Researchers will involve adult patients aged 19 to 70 who are undergoing planned surgeries with a certain anesthetic called rocuronium. Participants will be randomly assigned to receive different doses of sugammadex or an alternative treatment, and the study will carefully observe and measure any clenching that occurs within 10 minutes after the muscle relaxation is reversed.
To take part in this trial, individuals must be generally healthy (classified as ASA physical status I-II) and not have any neuromuscular disorders, kidney issues, or prior dental problems that could affect the results. The goal of the study is to find ways to make surgery safer by identifying factors that might increase the risk of this clenching, which will help doctors adjust treatments accordingly. If you or a loved one is considering participating, it’s an opportunity to contribute to important research that could improve patient care during surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible participants are adults aged 19-70 years, American Society of Anesthesiologists (ASA) physical status I-II, undergoing elective surgery under general anesthesia with rocuronium.
- Exclusion Criteria:
- • Exclusion criteria include neuromuscular disorders, renal impairment (creatinine clearance \< 30 mL/min), history of clenching or dental disease, allergy to study drugs, or emergency surgery.
About Wonkwang University Hospital
Wonkang University Hospital is a leading healthcare institution dedicated to advancing medical research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to enhancing patient care through innovative studies that explore new treatment modalities and therapeutic interventions. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, Wonkang University Hospital prioritizes patient safety and ethical standards while fostering collaborations that aim to translate scientific discoveries into effective clinical practices. The hospital’s focus on rigorous research methodologies and patient-centered approaches positions it as a key contributor to the advancement of medical knowledge and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iksan, Jeonbuk Do, Korea, Republic Of
Patients applied
Trial Officials
Cheolhyeong Lee, MD
Principal Investigator
Wonkwang University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported